Form D · Biotechnology
Atelerix Life Sciences Inc.
Charlottesville, VA · CIK 0001948853
Offering snapshot reported Oct 3, 2022 · SEC filing
- Reported sold
- $650K Offering amount: $3.5M
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 16, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 3, 2022 | Initial | $650,000 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-460533
Source: Form D, filed Oct 3, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| William Akridge | Director |
| Peter Barton Hutt | Director |
| David Kalergis | Director, Executive, Promoter |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
300 East Main Street Suite 202
Charlottesville, VA, 22902
Charlottesville, VA, 22902